Ajitha Azhakesan

Dr. Ajitha Azhakesan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in ACS Omega
Verified
Journal Article
Open access
AAAjitha Azhakesan
Ajitha Azhakesan
SKSujatha Kuppuswamy
Sujatha Kuppuswamy
The present study is intended to develop the high-performance liquid chromatography (HPLC) method for the analysis of Canagliflozin using the analytical quality by design (AQbD) approach. The key parameters were methodically optimized with the help of factorial experimental design, and contours were plotted when investigated using Design Expert software. A stability-indicating HPLC technique was developed and validated for the quantitative estimation of Canagliflozin, and its stability was assessed using various forced degradation conditions. Successful separation of Canagliflozin was accomplished using a Waters HPLC system with a photo diode array (PDA) detector and Supelcosil C18 column (250 × 4.6 mm, 5 μm) and 0.2% v/v solution of trifluoroacetic acid in water/acetonitrile (80:20% v/v) as the mobile phase maintaining the flow rate at 1.0 mL/min. The detection wavelength was 290 nm, and Canagliflozin got eluted at 6.9 min with a run time of 15 min. Canagliflozin peak purity values in all degradation conditions indicated that the peak is homogeneous, and therefore this method can be considered stability-indicating. The proposed technique was found to be specific, precise (% RSD about 0.66%), linear (12.6-37.9 μg/mL), rugged (overall % RSD about 0.50%), and robust. The standard and sample solutions were stable after 48 h (cumulative % RSD about 0.61%). The developed AQbD-based HPLC method can be used for the assay of Canagliflozin in Canagliflozin tablets of regular production batches and stability samples.

6 February 2024 in Journal of AOAC INTERNATIONAL
Verified
Journal Article
Closed access
SMSiri Chandana M.
Siri Chandana M.
SKSujatha K.
Sujatha K.
AAAjitha Azhakesan
Ajitha Azhakesan
NPNarendra Pentu
Narendra Pentu
SKSonia K.
Sonia K.
Background: Analytical quality by design (AQbD) affords a systematic scaffolding to triumph a continuously validated, robust assay as well as life cycle management. The resuscitative repurposed drug favipiravir, an oral drug approved for reemerging pandemic influenza in Japan in 2014, is used for the treatment of life-threatening pathogens such as Ebola, Lassa virus, and currently COVID-19. Favipiravir is gaining a great deal of medical importance due to its pharmaceutical applications. Objective: To develop and validate a risk-based stability-indicating RP-HPLC method employing an AQbD approach using Central Composite Design (Design Expert Software 13.0) for the estimation of favipiravir. Method: The Quality Target Product Profile optimized were flow rate and mobile phase composition, thus assessing the critical analytical attributes (retention time, tailing factor, and number of theoretical plates) as the constraints of method robustness. The proposed technique was optimized with a C18 (150 × 4.6 mm, 5 µm) column and 0.1% orthophosphoric acid buffer–acetonitrile (50:50, v/v) as the mobile phase at a flow rate of 1 mL/min using diode-array detector (230 nm) eluted favipiravir at 2.3 min. Results: The optimized method validated as per ICH guideline Q2 (R1) was found to be eco-friendly, simple, precise (RSD 0.0051–1.2%), accurate (99.86–100.22%), linear (25–150 µg/mL), rugged (RSD 0.70%), and robust (RSD 0.6–1.6%) with a limit of detection and limit of quantitation of 1.140 µg/mL and 4.424 µg/mL, respectively. Conclusion: Forced degradation studies (acidic, alkaline, thermal, photolytic, and oxidative conditions) revealed the suitability of the AQbD method for the analysis of favipiravir in tablet formulation.The developed and validated AQbD method is less time consuming and can be used in the industry for routine quality control/analysis of bulk drug and marketed Favipiravir products. Highlights: A robust Design of Experiment enhanced stability-indicating analytical method was developed and validated for the estimation of favipiravir. Furthermore, the contemporary method would aid in extending the analysis of favipiravir in other formulations.

28 February 2025 in Journal of Applied Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
NPNarendra Pentu
Narendra Pentu
AAAjitha Azhakesan
Ajitha Azhakesan
PKPasupuleti Kishore Kumar
Pasupuleti Kishore Kumar
Background: Using computational tools in drug discovery advanced the research in identifying new drug candidates for the benefit of the pharmaceutical industry and assessing the safety and pharmacokinetic profiles of phytochemicals. Understanding the inflammatory mechanism is not possible, but inflammatory signal transduction by cytokines can be mitigated by using the flavonoid class of drugs like flavonols. Methodology: A molecular docking study of flavonol compounds with proteins linked with inflammation was carried out using the AutodockVina program. SwissADME and pkCSM modules were used to assess the pharmacokinetic features of plant products. Compared to commercially available NSAIDs, flavonols had more excellent molecular docking scores. Results: Calculation of ADME features of flavonols with no carcinogenicity and low oral acute toxicity level. Compared to anti-inflammatory medicines, the Rutin docking score against COX-I (-8.7 kcal/mol) and the Galangin docking score against COX-II enzymes (-9.4 kcal/mol) had higher values. Discussion: Molecular docking studies exhibited the highest docking score for COX-I is Rutin -8.7 Kcal/mol and hydrogen bond with THR-89, PRO-84, LS-468, GLY-471, PHE-470. The highest docking for COX-II is Galangin -9.4 Kcal/mol and hydrogen bonding with VAL-349 and TYR-385. ADME/T studies were performed for all the flavonols. Rutin has the highest violations in drug-likeliness studies. Conclusion: Flavonols may be more effective anti-inflammatory medicines than commercial medications. By modifying the pharmacokinetic features of plant products through diverse formulation strategies, we can get these phytochemicals to their target sites with fewer adverse effects.

1 January 2022 in Reviews in Analytical Chemistry
Verified
Journal Article
Open access
PDF file
AAAjitha Azhakesan
Ajitha Azhakesan
SKSujatha Kuppuswamy
Sujatha Kuppuswamy
Sodium-glucose transporter 2 inhibitor emerges as the latest group of oral hypoglycemic agents, which shows insulin-independent pathology and provides an upper hand to enhance renal glucose elimination. Canagliflozin (CGN) was the number one drug, approved by FDA on 29th March 2013 for the treatment of type 2 diabetes mellitus. By totting up to its glucose-lowering effects, it exhibits beneficial effects on the heart and potentially on the kidneys. The study aims to summarize various analytical techniques, such as chromatography, spectrophotometry, and hyphenated techniques, such as Liquid chromatography with tandem mass spectrometry (LC-MS/MS) and Ultra performance liquid chromatography with tandem mass spectrometer (UPLC-MS) for the analysis of CGN. In the proposed work, we have reviewed various analytical methods reported for the estimation of CGN in biological matrices and Pharmaceuticals from various databases like ScienceDirect, Springer, PubMed, Scopus, Taylor & Francis, and Web of Science for the estimation of CGN. Various analytical methods adapted were high-performance liquid chromatography, UPLC, LC-MS/MS, high-performance thin-layer liquid chromatography, Fourier-transform infrared spectroscopy, spectrofluorimetry, and UV spectrophotometry. This current review presented the determination of CGN using various analytical techniques and biological matrices either in single or in combination with other hypoglycemic agents, as per International Conference on Harmonization guidelines. Further, some future trends that can be integrated were also suggested.

15 April 2019 in International Journal of Research in Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
AAAjitha Azhakesan
Ajitha Azhakesan
SKSujatha K
Sujatha K
AKAbbulu K
Abbulu K
A simple, precise, accurate Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) method was developed for the estimation of Garenoxacin mesylate in human plasma using Ciprofloxacin Hydrochloride as an internal standard. Chromatographic conditions used are stationary phase Zorbax Eclipse XDB C18 (250x4.6 mm, 5m), Mobile phase 0.1% orthophosphoric acid and Acetonitrile in the ratio of 50:50 (% v/v) and flow rate was maintained at 1.0 ml/min, detection wavelength was 240 nm, injection volume of 50 µL and the column temperature was set to 30°C. The retention time of Garenoxacin mesylate was found to be 4.0 min. % Coefficient of Variation of the Garenoxacin mesylate was found to be 4.30. % Recovery was obtained as 98.97%. The linearity of the proposed method was established in the concentration range of 0.04 to 4 µg/ml (Correlation Coefficient = 0.999). The lower limit of quantification was 0.04 μg/ml (S/N Ratio 21) which reach the level drug possibly found in human plasma. Further, the reported method was validated as per the ICH guidelines and found to be well within the acceptable range.

7 March 2025 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
VEVaishnavi C. E.
Vaishnavi C. E.
AAAjitha Azhakesan
Ajitha Azhakesan
NPNarendra Pentu
Narendra Pentu
Objective: This contemporary research reports the fabrication, optimization, and evaluation of Fucoidan (FDN)-loaded Nanosponges (NS) based gel for the treatment of rheumatoid arthritis. Methods: Risk assessment was performed, followed by screening and optimization of NS formulation by 32 factorial design using Design-Expert® software. FDN-loaded NS prepared by emulsion solvent evaporation technique was subjected to different solid and liquid state characterizations and subsequently loaded in carbopol gel. The effects of pro-inflammatory cytokines (IL-1 and TNFα) were evaluated using macrophage cells. Results: The physical and chemical characteristics exhibited by the prepared NS and gels (F1-F9) were found to be optimal. The optimization resulted in achieving formulation NS1 with 72.6% in vitro drug release and 8457cp viscosity and followed the Higuchi-matrix model. Histopathology studies revealed that prepared nanogel has promising anti-arthritic activity. The skin permeation studies showed that the optimized gel formulation was successful in stopping the drug from permeation through the skin. Moreover, the nanogel has depicted sustained drug release till 24 h. Conclusion: Hence, the NS-based the delivery system developed and assessed in the current research approach seemed to be auspicious concerning preventing rheumatoid arthritis along with practical utilization in the pharmaceutical field.